1503. Seroprevalence and Demographic Determinants of Human T-Lymphotropic Virus Type-1 and -2 Infections among First-time Blood Donors, U.S. 2000-2009
Session: Poster Abstract Session: HIV and Co-infections
Saturday, October 5, 2013
Room: The Moscone Center: Poster Hall C
Posters
  • Slide1.jpg (184.1 kB)
  • Background:  Human T-lymphotropic virus types 1 and 2 (HTLV-1 and -2) are prevalent at low-level among United States blood donors, but recent data on their prevalence is lacking. 

    Methods: Data on all first-time blood donors in a large network of United States blood centers was examined during the period 2000-2009. HTLV-1 and -2 antibody was measured by enzyme immunoassay (EIA) screening with confirmation by immunofluorescence or recombinant immunoblot. Prevalence rates were calculated, and odds ratios (OR) and 95% confidence intervals (CI) for associations with demographic characteristics were assessed using multivariable logistic regression.

    Results: Among 2,047,740 first-time donors, 104 donors were seropositive for HTLV-1 (prevalence 5.1 (95% CI: 4.1 - 6.1) per 100,000) and 300 donors were seropositive for HTLV-2 infection (prevalence 14.7 (95% CI 13.0 - 16.3) per 100,000). Prevalence was lower than reported in the 1990’s but stable from 2000 to 2009. HTLV-1 seropositivity was associated with female sex (OR = 1.56, 95% CI 1.05-2.32); older age; and Black (IR = 25.29, 9% CI 13.14- 48.68) and Asian (OR = 21.43, 95% CI 10.31-44.53) race/ethnicity. HTLV-2 seropositivity was associated with female sex (OR = 2.13, 95% CI 1.67-2.73); older age; and non-white race/ethnicity; residence in the Western (OR=4.12, 95% CI 2.16-7.82) and Southwestern (OR=2.47, 95% CI 1.28-4.78; both vs. Northern) US; and lower educational level.

    Conclusion: HTLV-1 and -2 prevalence among US blood donors has declined since the early 1990's. Higher prevalence of HTLV-2 in the West and Southwest may be attributed to endemic foci among Amerindians.

    Yun Brenda Chang, MPH1,2, Zhanna Kaidarova, MBA2, Daniel Hindes2, Marjorie Bravo3, Nancy Kiely, RN3, Hany Kamel, MD3, Denise Dubay3,4, Barbara Hoose3 and Edward Murphy Jr., MD, MPH2,4,5, (1)Department of Biostatistics, Columbia University, New York, NY, (2)Blood Systems Research Institute, San Francisco, CA, (3)Blood Systems, Inc, Scottsdale, AZ, (4)Blood Centers of the Pacific, San Francisco, CA, (5)Departments of Laboratory Medicine and Epidemiology/Biostatistics, University of California San Francisco, San Francisco, CA

    Disclosures:

    Y. B. Chang, None

    Z. Kaidarova, None

    D. Hindes, None

    M. Bravo, None

    N. Kiely, None

    H. Kamel, None

    D. Dubay, None

    B. Hoose, None

    E. Murphy Jr., None

    Findings in the abstracts are embargoed until 12:01 a.m. PST, Oct. 2nd with the exception of research findings presented at the IDWeek press conferences.